RT Journal Article
SR Electronic
T1 Outpatient treatment with concomitant vaccine-boosted convalescent plasma for patients with immunosuppression and COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.08.29.23293790
DO 10.1101/2023.08.29.23293790
A1 Ripoll, Juan G.
A1 Tulledge-Scheitel, Sidna M.
A1 Stephenson, Anthony A.
A1 Ford, Shane
A1 Pike, Marsha L.
A1 Gorman, Ellen K.
A1 Hanson, Sara N.
A1 Juskewitch, Justin E.
A1 Miller, Alex J.
A1 Zaremba, Solomiia
A1 Ovrom, Erik A.
A1 Razonable, Raymund R.
A1 Ganesh, Ravindra
A1 Hurt, Ryan T.
A1 Fischer, Erin N.
A1 Derr, Amber N.
A1 Eberle, Michele R.
A1 Larsen, Jennifer J.
A1 Carney, Christina M.
A1 Theel, Elitza S.
A1 Parikh, Sameer A.
A1 Kay, Neil E.
A1 Joyner, Michael J.
A1 Senefeld, Jonathon W.
YR 2024
UL http://medrxiv.org/content/early/2024/02/12/2023.08.29.23293790.abstract
AB Although severe coronavirus disease 2019 (COVID-19) and hospitalization associated with COVID-19 are generally preventable among healthy vaccine recipients, patients with immunosuppression have poor immunogenic responses to COVID-19 vaccines and remain at high risk of infection with SARS-CoV-2 and hospitalization. Additionally, monoclonal antibody therapy is limited by the emergence of novel SARS-CoV-2 variants that have serially escaped neutralization. In this context, there is interest in understanding the clinical benefit associated with COVID-19 convalescent plasma collected from persons who have been both naturally infected with SARS-CoV-2 and vaccinated against SARS-CoV-2 (“vax-plasma”). Thus, we report the clinical outcome of 386 immunocompromised outpatients who were diagnosed with COVID-19 and who received contemporary COVID-19 specific therapeutics (standard of care group) and a subgroup who also received concomitant treatment with very high titer COVID-19 convalescent plasma (vax-plasma group) with a specific focus on hospitalization rates. The overall hospitalization rate was 2.2% (5 of 225 patients) in the vax-plasma group and 6.2% (10 of 161 patients) in the standard of care group, which corresponded to a relative risk reduction of 65% (P=0.046). Evidence of efficacy in nonvaccinated patients cannot be inferred from these data because 94% (361 of 386 patients) of patients were vaccinated. In vaccinated patients with immunosuppression and COVID-19, the addition of vax-plasma or very high titer COVID-19 convalescent plasma to COVID-19 specific therapies reduced the risk of disease progression leading to hospitalization.IMPORTANCE As SARS-CoV-2 evolves, new variants of concern (VOCs) have emerged which evade available anti-spike monoclonal antibodies, particularly among immunosuppressed patients. However, high-titer COVID-19 convalescent plasma continues to be effective against VOCs because of its broad-spectrum immunomodulatory properties. Thus, we report clinical outcomes of 386 immunocompromised outpatients who were treated with COVID-19 specific therapeutics and a subgroup also treated with vaccine-boosted convalescent plasma. We found that administration of vaccine-boosted convalescent plasma was associated with a significantly decreased incidence of hospitalization among immunocompromised COVID-19 outpatients. Our data add to the contemporary data providing evidence to support the clinical utility of high-titer convalescent plasma as antibody replacement therapy in immunocompromised patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by United Health Group and Mayo Clinic.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Mayo Clinic Institutional Review Board determined that this study met the criteria for exemption.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesDatasets generated during this study may be available from corresponding authors on reasonable request. Requestors may be required to sign a data use agreement. Data sharing must be compliant with all applicable Mayo Clinic policies and those of the Mayo Clinic Institutional Review Board.